Pharmacokinetic profiling in mice following a single 5 mg/kg intraperitoneal dose revealed favorable tolerability, metabolic stability in human liver microsomes, and measurable CNS exposure, ...
The global rare NRG1 fusion market is set for significant growth from 2024 to 2035, driven by increased awareness of NRG1 fusions linked to cancers like pancreatic and non-small cell lung cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback